Implementation of Programmed Death-ligand 1 (PD-L1) Expression As a Prognostic Biomarker for Patients with Lung Cancer
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Lee Y
. Fixed-effect versus random-effect models for evaluating therapeutic preferences. Stat Med. 2002; 21(16):2325-30.
DOI: 10.1002/sim.1049.
View
2.
Jiang L, Wang L, Li P, Zhang X, Chen J, Qiu H
. Positive expression of programmed death ligand-1 correlates with superior outcomes and might be a therapeutic target in primary pulmonary lymphoepithelioma-like carcinoma. Onco Targets Ther. 2015; 8:1451-7.
PMC: 4474388.
DOI: 10.2147/OTT.S84234.
View
3.
Sha Z, Wei Y, Gao T, Luo Y, Chen J, Li T
. Clinical observation of pulmonary lymphoepithelioma-like carcinoma. J Thorac Dis. 2021; 13(10):5683-5690.
PMC: 8575801.
DOI: 10.21037/jtd-21-1369.
View
4.
Fang W, Hong S, Chen N, He X, Zhan J, Qin T
. PD-L1 is remarkably over-expressed in EBV-associated pulmonary lymphoepithelioma-like carcinoma and related to poor disease-free survival. Oncotarget. 2015; 6(32):33019-32.
PMC: 4741746.
DOI: 10.18632/oncotarget.5028.
View
5.
Li H, Xu Y, Wan B, Song Y, Zhan P, Hu Y
. The clinicopathological and prognostic significance of PD-L1 expression assessed by immunohistochemistry in lung cancer: a meta-analysis of 50 studies with 11,383 patients. Transl Lung Cancer Res. 2019; 8(4):429-449.
PMC: 6749117.
DOI: 10.21037/tlcr.2019.08.04.
View